• Free Investing e-Course
  • About
  • Advertise
  • Contact
  • Submit a Sponsored Post
Money Works Magazine
  • Life Sciences
  • Online Gaming
  • Real Estate
  • Download App
  • MORE
    • Technology
    • Personal Finance
    • Mining
DOWNLOAD YOUR COPY OF INVESTING IS FOR EVERYONE >
Money Works Magazine
  • Life Sciences
  • Online Gaming
  • Real Estate
  • Download App
  • MORE
    • Technology
    • Personal Finance
    • Mining
Money Works Magazine
Home Business

The Buzz Surrounding AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)

Money Works Magazine by Money Works Magazine
July 31, 2020
in Business
0
The Buzz Surrounding AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)
Share on FacebookShare on Twitter


 AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it had completed over 180,000 Cancer Differentiation Analysis (“CDA”) based tests as of July 15, 2020.

AnPac Bio had previously completed more than 169,000 CDA-based tests as of March 31, 2020. From April 1, 2020 to July 15, 2020, the Company completed over 10,000 commercial CDA-based tests and over 1,000 CDA-based tests for research purposes, which increased the cumulative number of CDA-based tests to over 180,000.

“We are honored to have achieved this milestone, which demonstrates the market-wide acceptance of our products. We offer a comprehensive product offering to meet different customers’ needs and to address this large and growing market. Our CDA-based test can detect and assess an individual’s overall risk of having or developing cancers, and a cancer risk assessment report is the final product of the test. The report presents the analytical parameters that our CDA test uses, including the PTF, CTF and overall CDA values,” said Dr. Chris Yu, CEO and Chairman of AnPac Bio.

Dr. Chris Yu continued, “Our CDA-based test is advanced in many ways. Unlike conventional cancer screening and detection approaches such as imaging technology and tissue biopsy, our CDA test uses liquid-based technology to detect the risk of cancer and non-cancerous diseases. It is minimally invasive, side effect-free and highly automated. Because it focuses on changes in cancer-related biophysical properties as a disease progresses, we believe that our CDA test can be used for multiple purposes, including early cancer screening and detection, and assistance in cancer diagnosis, prognosis and recurrence.”

For Full Release: https://www.globenewswire.com/news-release/2020/07/29/2069432/0/en/AnPac-Bio-Completes-Over-180-000-CDA-Based-Cancer-Risk-Assessment-Tests.html


Written by financial buzz.
View the original article at here.
Financial Buzz
www.financialbuzz.com

Recommended

Yggdrasil extends Veikkaus partnership

4 weeks ago
Japanese Live Entertainment Company, SCRAP, Enters China Market with Real-life Immersive NARUTO Game Collaboration

Strategy Analytics: Apple AirPods and Totally Wireless Bluetooth Headset Sales Soaring

1 year ago
Facebook Twitter LinkedIn

MWM is your friendly source of knowledge on financial freedom via investment opportunities and financial planning to make your money work for you.

  • Submit a Sponsored Post
  • Contact
  • Privacy Policy

Get the latest financial tips and news.
Sign up today.

  • This field is for validation purposes and should be left unchanged.

© 2019 Money Works Magazine . All rights reserved.

  • Home
  • Life Sciences
  • Personal Finance
  • Online Gaming
  • Mining
  • Technology
  • How To Trade
  • Free e-Course
  • Money Works Magazine App

© 2019 Money Works Magazine . All rights reserved.